Resibufogenin, one of bufadienolides in toad venom, suppresses LPS-induced inflammation via inhibiting NF-κB and AP-1 pathways
Affiliations
- 1 Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.
- 2 Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China. Electronic address: yqi@implad.ac.cn.
- PMID: 36252491
- DOI: 10.1016/j.intimp.2022.109312
Abstract
Toad venom is a traditional Chinese medicine that has a long history in treating infectious and inflammatory diseases, such as carbuncle, pharyngitis. As one of the major active components in toad venom, resibufogenin (RBG) possesses a variety of pharmacological activities, including lowering blood pressure, reducing proteinuria and preventing oxidative stress. But only its antitumor activity attracts widespread attention in these years. This study aimed to explore the nonnegligible anti-inflammatory activity of RBG in vivo and in vitro. In endotoxemia mice, a single intraperitoneal administration of RBG significantly lowered serum TNF-α, IL-6 and MCP-1 levels. In LPS-stimulated macrophages, RBG decreased LPS-induced pro-inflammatory mediators’ productions (e.g., iNOS, IL-6, TNF-α and MCP-1) through suppressing their transcriptions. Mechanism study showed that RBG hindered IκBα phosphorylation and prevented nuclear translocation of p65, thus inactivating nuclear factor-κB (NF-κB) signaling. Concurrently, RBG also dampened activator protein-1 (AP-1) signaling through inhibiting the phosphorylation levels of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK). Besides LPS (TLR4 ligand) model, RBG also inhibited Pam3CSK4 (TLR2 ligand)- or poly I:C (TLR3 ligand)-induced inflammatory reactions, suggesting that its target(s) site is(are) not on the cytomembrane. These findings not only support the pharmacological basis for the traditional use of toad venom in inflammatory diseases, but also provide a promising anti-inflammatory candidate.
Keywords: Activator protein-1 (AP-1); Inflammation; Lipopolysaccharide; Macrophage; Nuclear factor-κB (NF-κB); Resibufogenin.
长核酸转染试剂Entranster™-H4000 已有 118 篇已发表文献
同类研究
- Bone Joint Res. 2026 Jul 23;15(7):914-926.doi: 10.1302/2046-3758.157.bjr-2025-0343.r1. CDK12 mediates the inhibition eff…
- Plants (Basel). 2026 Jul 18;15(14):2199.doi: 10.3390/plants15142199. Anti-Complement, Anti-Oxidative, and Anti-Inflammat…
- Cell Death Differ. 2026 Jun 26.doi: 10.1038/s41418-026-01802-w. SUMOylation-stabilized G6PD orchestrates metabolic rewir…
- Dev Comp Immunol. 2026 Jun:179:105625.doi: 10.1016/j.dci.2026.105625. Epub 2026 May 12. Bombyx mori IML-2 modulates intr…
- Pestic Biochem Physiol. 2026 May:220:107056.doi: 10.1016/j.pestbp.2026.107056. Epub 2026 Mar 7.